Wall Street futures opened higher on Tuesday as investors assessed a fresh batch of corporate earnings. The Dow Jones Industrial Average rose 585.4 points, or 1.34%, at the open to 44173.64. The S&P 500 rose 91.93 points, or 1.47%, to 6336.63, while the Nasdaq Composite rose 21.07 points, or 0.12%, to 21081.03.
Palantir Technologies reported its fiscal Q2 2025 results, surpassing $1 billion in quarterly revenue for the first time, a 48% year-over-year jump to approximately $1.004 billion, well above analyst estimates of $940 million. Adjusted earnings per share came in at 16 cents, beating the expected 14 cents, while net income soared 144% to $326 million.
The company significantly raised its full-year revenue forecast to a range of $4.14 billion to $4.15 billion, up from the previous guidance of around $3.9 billion. It also projected Q3 revenues between $1.083 billion and $1.087 billion, topping Wall Street expectations.
Shares of Palantir surged to all-time highs and have more than doubled in 2025. CEO Alex Karp noted that the company plans to drive further revenue growth while reducing headcount, citing an AI-powered push for greater efficiency, though specifics on workforce changes remain unclear.
Hims & Hers Health disappointed investors by missing second-quarter estimates and issuing a weak forecast for Q3. Meanwhile, Denny’s posted earnings below analyst expectations as same-store sales declined, reflecting ongoing concerns about consumer spending in the U.S.
Vertex Pharmaceuticals posted robust Q2 2025 results, with total revenue rising 12% year-over-year to $2.96 billion, fueled by strong demand for its cystic fibrosis (CF) therapies and early sales from new product launches including ALYFTREK, CASGEVY, and JOURNAVX.
Revenue climbed 14% to $1.85 billion, while international revenue grew 8% to $1.12 billion. The company reported adjusted earnings per share of $4.52, exceeding analyst estimates of $4.27. Net income reached $1.2 billion on a non-GAAP basis, a sharp turnaround from the net loss recorded in Q2 2024. Operating expenses decreased year-over-year, as the prior period included one-time acquisition-related charges, although Vertex continued to ramp up investments in R&D and product commercialization